for the Alzheimer's Disease Neuroimaging Initiative IMPORTANCE Late-onset Alzheimer disease (AD) is highly heritable. Genome-wide association studies have identified more than 20 AD risk genes. The precise mechanism through which many of these genes are associated with AD remains unknown. 
S poradic Alzheimer disease (AD) is 70% to 80% heritable. 1, 2 The strongest genetic risk factor for AD is the apolipoprotein E (APOE) gene (OMIM 107741) . The APOE ε4 allele carries the greatest risk through the reduction of β-amyloid (Aβ) clearance. [3] [4] [5] APOE ε4 carriers have a significantly higher prevalence of Pittsburgh compound B uptake than noncarriers across all disease stages, 6 including presymptomatic amyloidosis in cognitively normal control individuals. 7 Peripheral blood apoE protein levels correlate with amyloid positron emission tomography (PET) binding. 8, 9 These data indicate that imaging phenotypes can provide meaningful information related to gene function and pathophysiologic findings. Previous large-scale genome-wide association studies (GWASs) [10] [11] [12] [13] [14] [15] have identified and validated 20 novel AD genetic risk loci. Few of these loci are in or near genes associated with Aβ aggregation and clearance and are thought to influence amyloid deposition. 15, 16 For the remainder, the precise disease-associated mechanism remains unknown. Several imaging genetics studies [16] [17] [18] [19] [20] have reported associations of some of the AD risk genes with brain amyloidosis or neurodegeneration. Phosphatidylinositol-binding clathrin assembly protein (PICALM) (OMIM 603025) rs3851179, bridging integrator 1 (BIN1) (OMIM 601248) rs7561528, complement component receptor 1 (CR1) rs1408077 (OMIM 120620), adenosine triphosphate-binding cassette subfamily A member7(ABCA7) (OMIM 605414) rs3764650, and membranespanning 4-domains, subfamily A, member 6a (MS4A6A) (OMIM 606548) rs610932 are associated with cortical and hippocampal atrophy. 21,22 ABCA7 rs3764650 and rs3752246; BIN1 rs744373; CR1 rs6701713, rs3818361, and rs6656401; and clusterin (CLU) rs3818361 (OMIM 185430) are associated with amyloid deposition. Although these studies enrich the imaging genetics field, they also have significant shortcomings. Many of these research studies have focused on a single variant 19 or a few variants [16] [17] [18] [22] [23] [24] [25] while ignoring the complex polygenic disease background. In addition, all analyses of geneendophenotype associations to date have largely used averaged phenotypic records across all disease stages. Such an approach is justified if the risk variant has a static or conserved effect during the disease course. However, considering the complicated and constantly evolving disease pathophysiologic process with early amyloid deposition, later onset of neuronal degeneration, and variable degree of inflammation, we considered stage-dependent genetic associations. Furthermore, improved understanding of the polygenetic risk factors for AD could enable personalized risk assessment, whereas an indepth characterization of disease-associated mechanism could lead to new therapeutic avenues.
We report a comprehensive analysis of the associations of all well-validated AD risk variants with brain amyloidosis. Our goal was to establish their relative contribution to the amyloid burden. We hypothesized that our multivariable analytic approach would help us more accurately model the probability distribution of our imaging outcome measure and that we would detect several genetic variants in addition to APOE ε4 that are associated with brain amyloidosis. In addition, we hypothesized that we might also find stage-dependent associations with amyloid accumulation.
Methods

Participants
Data used in this study were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni .loni.usc.edu). The ADNI is a longitudinal study with approximately 50 sites across the United States and Canada that was launched in 2003 (http://adni.loni.usc.edu). The goal of the ADNI is to track the progression of AD by using clinical and cognitive tests, magnetic resonance imaging (MRI), fludeoxyglucose PET, amyloid PET, cerebrospinal fluid, and blood biomarkers. The institutional review boards of all sites participating in the ADNI provided review and approval of the ADNI data collection protocol.
The clinical description of the ADNI cohort has been previously published.
26-28 Diagnosis of AD was based on the National ADNI-2 and the ADNI-Grand Opportunity (GO) participants were genotyped using the Illumina HumanOmniExpress BeadChip (Illumina Inc) according to the manufacturer's protocol. We focused on the 20 well-established AD risk genes identified and validated in the largest AD GWASs to date. [10] [11] [12] [13] [14] [15] In addition to the variants reported in these articles, we included all other variants that were previously associated with brain amyloidosis [16] [17] [18] [19] (eTable 1 in the Supplement), which yielded a total of 36 variants. Missing genotypes (eTable 2 in the Supplement)wereimputed using MACH and minimac in a 2-stage procedure using the 1000 Genomes project pilot data as a reference panel. Minimac yielded the posterior probabilities of the imputed genotypes at ungenotyped marker loci for each individual. The threshold to accept each imputed genotype was set at r 2 =0.30.
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Nine genes were represented by more than 1 singlenucleotide polymorphism (SNP). Because linkage disequilibrium (LD) introduces colinearity bias, we performed LD analyses followed by Cohen κ statistics (eFigure 1 and eTable 3 in the Supplement). When choosing between 2 variants with significant overlap (high LD and high κ), we retained the variant with least data missingness. Our final number of variants was thus reduced to 27. ABCA7, BIN1, CLU, CR1, ephrin receptor EphA1 (EPHA1) (OMIM 179610), and sortilin-related receptor (SORL1) (OMIM 602005) were represented with more than 1 variant in the analyses (eTable 3 in the Supplement).
Allele frequencies for each gene variant were assessed. Genotypes were collapsed when the minor allele homozygote frequency was less than 2% as follows: ABCA7 rs3764650 GG/GT vs TT, Cass scaffolding protein family member 4 (CASS4) (HGNC 15878) rs7274581 CC/TC vs TT, CLU rs9331949 AG/GG vs AA, desmoglein 2 (DSG2) (OMIM 125671) rs8093731 TT/TC vs CC, fermitin family homologue 2 FERMT2 (OMIM 607746) rs17125944 CC/TC vs TT, and SORL1 rs112183431 CC/TC vs TT. The remaining variants were coded by minor allele dosage.
Florbetapir F 18 PET Data Acquisition Protocol and Analyses
The florbetapir F 18 PET acquisition and preprocessing protocols are available at http://www.adni-info.org. In our main analyses, we used the mean whole-`brain standard uptake volume ratios (SUVRs) from University of California, Berkeley downloaded from the ADNI database (http://adni.loni.usc .edu). This variable was obtained by averaging the SUVRs obtained using whole cerebellum as the reference region across the frontal, anterior-posterior cingulate, lateral-parietal, and lateral-temporal gray matter regions. 36 The University of California, Berkeley, protocols for 18 F-florbetapir preprocessing, coregistration, and normalization have been previously described.
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To visualize the regional pattern of associations in 3 dimensions, we downloaded all preprocessed 18 F-florbetapir data from the Laboratory of Neuroimaging Image Data Archive (https://ida.loni.usc.edu). We aligned the images to the corresponding MRI from the same visit, normalized to MNI space using measures obtained from the MRI spatial transformation and intensity normalized to the intensity of the whole cerebellum reference region to create SUVR images, as previously described.
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Statistical Analysis R Statistical Analyses Clinical and demographic characteristics (age, sex, educational level, MMSE, APOE ε4 genotype, and diagnosis) for each variant were compared using t tests or χ 2 tests with 2-sided P values as appropriate. Stepwise multivariable linear regression models with all 27 AD risk variants were performed first in the pooled sample and second in each diagnostic category using amyloid PET mean SUVR as the outcome measure. An additional model in the pooled sample using only amyloidpositive individuals (SUVR>1.17) is available in the eResults in the Supplement. All regression models included age, sex, and APOE ε4 genotype as covariates. The regression model for the pooled sample was also corrected for diagnosis. The decision to exclude variables was based on the Akaike information criterion critical P value threshold of .16. 38 Because we included only previously validated candidate genes, our significance threshold was set at P < .05. Correction for false discovery rate (FDR) was applied.
Analyses in Imaging Space
All imaging analyses were performed in an exploratory fashion. To explore the spatial distribution of the associations, we reproduced the final stepwise regression models using voxelwise regression in Statistical Parametric Mapping 8 (SPM8; Wellcome Department of Cognitive Neuroscience). The SPM8 models included all variants retained in the R statistical models (including those that were retained based on the Akaike information criterion) covaried for age, sex, and APOE ε4 genotype. The pooled model also included diagnosis as a covariate. Because of the exploratory nature of our secondary results, we allowed a less stringent visualization threshold: voxelwise threshold of P < .01 (uncorrected) with a minimum cluster size (k) of 50 voxels. We also computed familywise error (FWE) and FDR-corrected cluster and peak statistics as appropriate.
Results
The study population was composed of participants from the ADNI-1, ADNI-2, and ADNI-GO stages 39 . Group comparisons of demographic characteristics and distribution of the genotypes that were retained in the regression models are given in Table 1 . APOE ε4 had significant associations with brain amyloidosis (eFigure 2 in the Supplement). There were no significant differences in age, sex, educational level, MMSE score, and APOE ε4 distribution between carriers and noncarriers or by allele dosage for any of the genotypes except for zinc finger CW-type and PWWP domain containing 1 (ZCWPW1) (HGNC 23486) for which risk allele homozygotes were less educated (P = .02).
Pooled Sample
In the pooled sample, the stepwise linear regression model achieved an R 2 of 0.35 (95% CI, 0.33-0.37; P < .001). ABCA7
rs11771145 (χ 2 = 4.08, FDR-corrected P = .03), and PICALM rs3851179 (χ 2 = 3.67, FDR-corrected P = .04) were significantly associated with mean SUVR in the pooled sample. Other associations were as follows: ZCPWPW1 rs1476679 (χ 2 =2. 7 4, FDR-corrected P = .08), FERMT2 rs17125944 (χ 2 = 3.63, FDRcorrected P = .08), and protein tyrosine-kinase 2β (PTK2B) rs28834970 (OMIM 601212)(χ 2 = 2.52, FDR-corrected P = .01).
ABCA7 rs3764650 and CLU rs11136000 were included in the model based on the Akaike selection criterion. A reduced model that included only age, sex, educational level, and APOE ε4 achieved a reduced R 2 of 0.31 (95% CI, 0.29-0.33). The betweenmodel difference in R 2 and reduced R 2 was 0.038 (95% CI, 0.029-0.047). Figure 1 and Figure 2 show these associations and Table 2 gives FWE-and FDR-corrected cluster-level results and within-cluster peak associations for genetic variants identified in our models.
Interaction Analyses
To further test for the presence of a stage-specific association, we conducted a linear regression analysis in the pooled sample including interaction terms. FERMT2 was the only variant that had a significant interaction (FERMT2 × diagnosis χ 2 = 3.53, FDR-corrected P = .05). The effect sizes for the remaining genes remained unchanged. Figure 3 shows the β-coefficient maps of the main effect size of FERMT2 and its interaction with diagnosis as well as the FERMT2 effect size within each diagnostic group.
Exploratory Analyses Within Diagnostic Groups
In the control group, the model achieved an R 2 of 0.17 (95% CI, 0.14-0.21; P < .001; reduced R 2 = 0.14; 95% CI, 0.11-0.17; R rs1131497 (χ 2 = 3.66, FDR-corrected P = .03) were significantly associated with mean SUVR. The association for ABCA7 rs3764650 was χ 2 = 2.9 (FDR-corrected P = .09).
In the dementia group, the model achieved an R 2 of 0.35 (95% CI, 0.29-0.41; P < .0001; reduced R 2 = 0.22; 95% CI, 0.16-0.28; R 2 -reduced R 2 difference = 0.13; 95% CI, 0.09-0.17).
Other associations were as follows: EPHA1 rs11771145 (χ 2 = 5.05, FDR-corrected P = .01), ZCWPW1 rs1476679 (χ 2 = 3.79, FDRcorrected P = .04), DSG2 rs8093731 (χ 2 = 3.27, FDR-corrected P = .08), CLU rs9331949 (χ 2 = 4.09, FDR-corrected P = .058), and SORL1 rs1131497 (χ 2 = 2.51, FDR-corrected P = .08). Figure 1 and Figure 2 present exploratory visualization of these associations, and Table 2 presents the FWE-and FDRcorrected cluster-level results and within-cluster peak associations for genetic variants identified in our models.
Discussion
Improved understanding of the polygenetic risk factors that are associated with AD could enable personalized risk assessment. To our knowledge, this is the first comprehensive analysis of the association of the top 20 AD risk variants with brain amyloidosis. We were able to confirm the previously reported association between ABCA7 and brain amyloidosis as described by Shulman et al 16 and Hughes et al. 18 Our study found that after APOE ε4, ABCA7 has the strongest associa- tion with amyloid deposition. We were unable to confirm the reported associations of CR1 20 likely because the associations previously reported were determined using a univariable approach. It is plausible that the previously reported CR1 association is better accounted for by other AD-related genes, which were not part of the original analysis. We also found evidence of a stage-dependent gene association of FERMT2 with brain amyloidosis. This is, to our knowledge, the first report of such an association. Several genes had associations with brain amyloidosis. ABCA7 encodes a 2146-amino acid ABC family transporter protein. 40 The ABC protein family is responsible for the transport of a variety of molecules across cellular membranes, primarily lipids. ABCA7 is expressed in nervous tissue, with the highest expression in microglia. 
ZCWPW1 rs1476679
Images were visualized using P < .01 (uncorrected) and cluster size (k) of 50 voxels. Scale indicates T values. 82 The neuronal SORL1 protein level determines cognitive decline and conversion from MCI to AD. 83 The protein level also correlates with the levels of the APP soluble products that result from β-secretase cleavage. 84 An SNP in LD with our variant (rs1133174) has also been linked to brain atrophy in AD. 85 The ZCWPW1 gene codes for a 648-amino acid protein. ZCWPW1 is considered to be a risk gene for late-onset AD. Its proposed mechanism of action is through epigenetic regulation of gene expression.
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Strengths and Limitations
Several strengths and limitations of our study warrant discussion. One of the major strengths lies in the careful clinical, biomarker, and genetic characterization of all individuals enrolled in the ADNI. The ADNI protocol uses unified subject assessment, standardization of all imaging, biofluid and DNA and RNA data collection and processing, and meticulous data quality control across all study sites. Another strength of the study is the fairly large sample size that allowed us to achieve enough statistical power to test the associations of 27 AD-associated risk variants using a polygenic model. A major limitation of our study is that we only report crosssectional analyses; thus, we cannot make definitive conclusions regarding genetic effects on amyloid deposition over time. From our cross-sectional observations across the disease continuum, we drew conclusions about early vs late genetic influences on brain amyloidosis that will need to be further tested using a longitudinal design, which is what we plan to do next. Another limitation of our work is that the sample size was not big enough to allow us to test for gene-gene and geneenvironment interactions. Last but not least, the ADNI uses rigorous exclusion criteria typical of clinical trials, rendering the ADNI cohort not representative of the general population, which may negatively affect the generalizability of our results. Thus, our next steps will be to validate our findings in a large, independent, longitudinal cohort.
Conclusions
We found an association of genetic variants with brain amyloidosis, the salient pathognomonic feature of AD. Four of the genetic variants reported here, ABCA7, CLU, EPHA1, and SORL1, have been previously linked to the amyloidogenic AD pathways. To our knowledge, we are the first to report a stagespecific association for a genetic variant (ie, FERMT2).
